Advertisement
UK markets closed

  • FTSE 100

    8,213.49
    +41.34 (+0.51%)
     

  • FTSE 250

    20,164.54
    +112.21 (+0.56%)
     

  • AIM

    771.53
    +3.42 (+0.45%)
     

  • GBP/EUR

    1.1652
    -0.0031 (-0.26%)
     

  • GBP/USD

    1.2546
    +0.0013 (+0.11%)
     

  • Bitcoin GBP

    50,743.82
    +595.09 (+1.19%)
     

  • CMC Crypto 200

    1,325.68
    +48.70 (+3.81%)
     

  • S&P 500

    5,127.79
    +63.59 (+1.26%)
     

  • DOW

    38,675.68
    +450.02 (+1.18%)
     

  • CRUDE OIL

    77.99
    -0.96 (-1.22%)
     

  • GOLD FUTURES

    2,310.10
    +0.50 (+0.02%)
     

  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     

  • HANG SENG

    18,475.92
    +268.79 (+1.48%)
     

  • DAX

    18,001.60
    +105.10 (+0.59%)
     

  • CAC 40

    7,957.57
    +42.92 (+0.54%)
     
MONEY:

Best savings accounts that offer above inflation rates

Where to find a top-rated deal that works for you

AstraZeneca trumpets progress in cancer, other drugs

Reuters - UK Focus

LONDON, Nov 18 (Reuters) - AstraZeneca (NYSE: AZN - news) , determined to show it has a strong independent future after seeing off a $118 billion bid from Pfizer (NYSE: PFE - news) in May, said it had made good progress in developing a pipeline of new drugs.

The company flagged its "industry-leading" portfolio of immune-boosting cancer drugs and said that across all disease areas it had the potential to secure between eight and 10 approvals for new medicines in 2015-2016.

AstraZeneca executives will present further details at a six-hour investor meeting later on Tuesday. The event comes just eight days before British takeover rules allow Pfizer to renew its pursuit, an option some investors now see as unlikely.

(Reporting by Ben Hirschler; editing by Kate Holton)